As of 2026-03-18, the Relative Valuation of Enanta Pharmaceuticals Inc (ENTA) is (41.78) USD. This relative valuation is based on P/E multiples. With the latest stock price at 13.27 USD, the upside of Enanta Pharmaceuticals Inc based on Relative Valuation is -414.9%.
The range of the Relative Valuation is (35.00) - (50.34) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 14.2x - 20.4x | 17.8x |
| Forward P/E multiples | 13.4x - 20.4x | 16.1x |
| Fair Price | (35.00) - (50.34) | (41.78) |
| Upside | -363.8% - -479.3% | -414.9% |
| Date | P/E |
| 2026-03-16 | -5.24 |
| 2026-03-13 | -5.15 |
| 2026-03-12 | -5.44 |
| 2026-03-11 | -5.75 |
| 2026-03-10 | -5.66 |
| 2026-03-09 | -5.63 |
| 2026-03-06 | -5.49 |
| 2026-03-05 | -5.57 |
| 2026-03-04 | -6.25 |
| 2026-03-03 | -5.97 |
| 2026-03-02 | -5.89 |
| 2026-02-27 | -5.80 |
| 2026-02-26 | -5.85 |
| 2026-02-25 | -5.94 |
| 2026-02-24 | -5.98 |
| 2026-02-23 | -5.47 |
| 2026-02-20 | -5.48 |
| 2026-02-19 | -5.68 |
| 2026-02-18 | -5.63 |
| 2026-02-17 | -5.62 |
| 2026-02-13 | -5.62 |
| 2026-02-12 | -5.61 |
| 2026-02-11 | -5.78 |
| 2026-02-10 | -5.73 |
| 2026-02-09 | -5.61 |
| 2026-02-06 | -5.48 |
| 2026-02-05 | -5.26 |
| 2026-02-04 | -5.47 |
| 2026-02-03 | -5.50 |
| 2026-02-02 | -5.35 |
| 2026-01-30 | -5.23 |
| 2026-01-29 | -5.23 |
| 2026-01-28 | -5.13 |
| 2026-01-27 | -5.27 |
| 2026-01-26 | -5.24 |
| 2026-01-23 | -5.28 |
| 2026-01-22 | -5.19 |
| 2026-01-21 | -5.10 |
| 2026-01-20 | -5.07 |
| 2026-01-16 | -5.12 |
| 2026-01-15 | -5.42 |
| 2026-01-14 | -5.61 |
| 2026-01-13 | -5.33 |
| 2026-01-12 | -5.24 |
| 2026-01-09 | -5.32 |
| 2026-01-08 | -5.45 |
| 2026-01-07 | -5.63 |
| 2026-01-06 | -5.51 |
| 2026-01-05 | -5.64 |
| 2026-01-02 | -5.85 |